Lysogene S.A.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a LYS.PA research report →
About the company
Lysogene S. A. is a biopharmaceutical firm specializing in gene therapy, dedicated to discovering and advancing treatments for children affected by severe neurodegenerative lysosomal storage disorders.
- CEO
- Karen Pignet-Aiach MBA
- IPO
- 2017
- Employees
- 22
- HQ
- Neuilly-sur-Seine, FR
Price Chart
- Market Cap
- $4.95M
- P/E
- -0.34
- P/S
- 1.33
- P/B
- -1.08
- EV/EBITDA
- -0.19
- Div Yield
- 0.00%
- Gross Margin
- 49.37%
- Op Margin
- -356.23%
- Net Margin
- -366.42%
- ROE
- -1129.83%
- ROIC
- -236.37%
- Revenue
- $3.73M · -72.09%
- Net Income
- $-13,671,000 · -167.80%
- EPS
- $-0.81 · -153.13%
- Op Income
- $-13,291,000
- FCF YoY
- -1.45%
- 52W High
- $0.82
- 52W Low
- $0.23
- 50D MA
- $0.28
- 200D MA
- $0.39
- Beta
- 0.91
- Avg Volume
- 0
Get TickerSpark's AI analysis on LYS.PA
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our LYS.PA coverage
Recent articles, reports, and earnings notes.
No research on LYS.PA yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate LYS.PA report →Similar companies
Peers in the same neighborhood.